急诊科经分析确认γ-羟丁酸(GHB)阳性患者的特征:临床表现、多药使用、去向及对重症监护资源利用的影响
本研究为急诊科入院血液精神活性物质检测研究的一部分,在15个月内纳入澳大利亚阿德莱德四家都市急诊科因药物中毒症状就诊的患者1120例,采集去标识化血样行全面毒理学分析,GHB采用酸催化环化后液-液萃取和气相色谱-质谱法测定。2019年3月至2020年5月共1120例入组,309例(27.6%)GHB阳性,其中256例(83%)同时甲基苯丙胺阳性;GHB阳性者最常见临床表现为中枢神经系统抑制(89%)。GHB阳性与性别显著相关,女性阳性比例32%高于男性25%(P=0.0155)。血GHB浓度范围10–651 mg/L(0.096–6.2 mmol/L),浓度升高与严重毒性相关。69.2%的GHB阳性患者经急诊科或其附属短留病房处理并离院,但GHB阳性者入住ICU比例28.2%显著高于阴性者12.7%(卡方=36.85,P<0.001),GHB阳性病例占所有研究相关ICU入住的45.8%。
要点
- 因药物中毒症状就诊的急诊患者中GHB阳性率达27.6%(309/1120),其中83%(256例)合并甲基苯丙胺阳性,提示常规毒理筛查外应警惕GHB。
- GHB阳性者最常见表现为中枢神经系统抑制(89%),血GHB浓度10–651 mg/L(0.096–6.2 mmol/L),浓度升高与严重毒性相关。
- GHB阳性者ICU入住率28.2%,显著高于GHB阴性者的12.7%(卡方=36.85,P<0.001),GHB阳性病例占所有研究相关ICU入住的45.8%。
- 多数GHB阳性患者(69.2%)经急诊科或其附属短留病房处理并离院,但仍有近三成需ICU级别救治。
- 女性GHB阳性比例32%高于男性25%(P=0.0155),尽管男性在绝对数量上占多数。
适用人群与场景
- 2019年3月至2020年5月共15个月期间,就诊于澳大利亚阿德莱德四家都市急诊科、因药物中毒症状入组急诊科入院血液精神活性物质检测研究的患者,共1120例。
诊断标准与关键阈值
- GHB阳性判定:血样经酸催化环化后液-液萃取、气相色谱-质谱法测定。
- 血GHB浓度范围10–651 mg/L(0.096–6.2 mmol/L),浓度升高与严重毒性相关。
红旗征与不能漏的情况
- GHB阳性者最常见临床观察为中枢神经系统抑制(89%)。
- GHB阳性者入住ICU比例28.2%,显著高于GHB阴性者的12.7%(卡方=36.85,P<0.001)。
研究设计与关键结果
- 研究类型:急诊科入院血液精神活性物质检测研究的一部分,纳入四家都市急诊科因药物中毒症状就诊的患者1120例。
- GHB阳性309例(27.6%),其中256例(83%)同时甲基苯丙胺阳性。
- GHB阳性者最常见临床观察为中枢神经系统抑制(89%)。
- GHB状态与性别显著相关:女性阳性比例32%高于男性25%(P=0.0155),男性在绝对数量上占多数。
- 血GHB浓度10–651 mg/L(0.096–6.2 mmol/L),浓度升高与严重毒性相关。
- 69.2%的GHB阳性患者经急诊科或其附属短留病房处理并离院。
- GHB阳性者入住ICU比例28.2%,GHB阴性者12.7%(卡方=36.85,P<0.001)。
- GHB阳性病例占所有研究相关ICU入住的45.8%。
证据类型、等级与局限
- 证据类型:急诊科入院血液精神活性物质检测研究(观察性研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 因药物中毒症状就诊的急诊患者中GHB检测阳性常见(27.6%),且常合并甲基苯丙胺(83%),接诊此类患者时需考虑GHB暴露。
- GHB阳性者中枢神经系统抑制占89%,且ICU入住率28.2%显著高于阴性者12.7%,提示GHB阳性患者对重症监护资源利用影响大。
- 多数GHB阳性患者(69.2%)可经急诊科或其附属短留病房处理并离院。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Gamma-hydroxybutyrate is a potent central nervous system depressant with a narrow recreational dose window and analytical detection time. We describe data relating to intoxicated patients presenting to emergency departments across metropolitan Adelaide who tested positive for gamma-hydroxybutyrate. This work was part of the Emergency Department Admission Blood Psychoactive Testing study.
METHODS: Over a 15-month period, patients presenting to four metropolitan emergency departments with symptoms of drug intoxication were enrolled in the study. The methodology involved the collection of demographic and clinical data and a de-identified blood sample which underwent comprehensive toxicological analysis. Gamma-hydroxybutyrate was determined using an acid-catalysed cyclisation followed by liquid-liquid extraction and gas chromatography-mass spectrometry. Data relating to samples positive for gamma-hydroxybutyrate were examined.
RESULTS AND DISCUSSION: A total of 1120 patients were enrolled between March 2019 and May 2020, 309 of whom were positive for gamma-hydroxybutyrate (27.6%). Of these, 256 (83%) were also positive for metamfetamine (methamphetamine). The most common clinical observation in gamma-hydroxybutyrate-positive patients was central nervous system depression (89%). There was a significant relationship between gamma-hydroxybutyrate status and sex; although males outnumbered females in absolute terms, a higher proportion of females (32%) tested positive for gamma-hydroxybutyrate than males (25%, P = 0.0155). Blood gamma-hydroxybutyrate concentrations ranged from 10 to 651 mg/L (0.096-6.2 mmol/L) and increasing gamma-hydroxybutyrate concentration correlated with severe toxicity. The presence of gamma-hydroxybutyrate had a significant impact on the patient discharge destination: the majority (69.2%) of gamma-hydroxybutyrate-positive patients were managed and discharged from the emergency department or their attached short stay wards. A significantly higher proportion of gamma-hydroxybutyrate-positive patients were admitted to the intensive care unit (28.2%) compared with gamma-hydroxybutyrate-negative patients (12.7%, chi-squared = 36.85, P <0 .001). Gamma-hydroxybutyrate positive cases accounted for 45.8% of all study-related intensive care unit admissions.
CONCLUSIONS: Gamma-hydroxybutyrate is commonly detected in illicit drug-related emergency department presentations and is detected disproportionately in the patient cohort who require intensive care unit level care.
参考来源
- Stockham P, Partridge E, Alfred S, et al. Characteristics of analytically confirmed gamma-hydroxybutyrate (GHB) positive patients in the emergency department: presentation, poly-drug use, disposition and impact on intensive care resource utilisation. Clin Toxicol (Phila). 2023. PMID: 37129222. doi:10.1080/15563650.2023.2178933
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。